- Home
- OCUL vs NTLA Comparison
OCUL vs NTLA Comparison
Compare OCUL & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCUL
- NTLA
- Stock Information
- Founded
- OCUL 2006
- NTLA 2014
- Country
- OCUL United States
- NTLA United States
- Employees
- OCUL N/A
- NTLA N/A
- Industry
- OCUL Biotechnology: Pharmaceutical Preparations
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- OCUL Health Care
- NTLA Health Care
- Exchange
- OCUL Nasdaq
- NTLA Nasdaq
- Market Cap
- OCUL 1.2B
- NTLA 1.0B
- IPO Year
- OCUL 2014
- NTLA 2016
- Fundamental
- Price
- OCUL $7.27
- NTLA $7.17
- Analyst Decision
- OCUL Strong Buy
- NTLA Buy
- Analyst Count
- OCUL 9
- NTLA 18
- Target Price
- OCUL $16.22
- NTLA $39.44
- AVG Volume (30 Days)
- OCUL 1.8M
- NTLA 3.2M
- Earning Date
- OCUL 03-03-2025
- NTLA 05-08-2025
- Dividend Yield
- OCUL N/A
- NTLA N/A
- EPS Growth
- OCUL N/A
- NTLA N/A
- EPS
- OCUL N/A
- NTLA N/A
- Revenue
- OCUL $63,723,000.00
- NTLA $57,877,000.00
- Revenue This Year
- OCUL $14.02
- NTLA N/A
- Revenue Next Year
- OCUL $15.47
- NTLA N/A
- P/E Ratio
- OCUL N/A
- NTLA N/A
- Revenue Growth
- OCUL 9.03
- NTLA 59.55
- 52 Week Low
- OCUL $4.06
- NTLA $8.03
- 52 Week High
- OCUL $11.78
- NTLA $28.18
- Technical
- Relative Strength Index (RSI)
- OCUL 45.35
- NTLA 30.71
- Support Level
- OCUL $7.36
- NTLA $8.50
- Resistance Level
- OCUL $8.04
- NTLA $9.38
- Average True Range (ATR)
- OCUL 0.45
- NTLA 0.62
- MACD
- OCUL -0.02
- NTLA -0.15
- Stochastic Oscillator
- OCUL 13.61
- NTLA 5.78
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.